Treatment with zerlasiran produced sustained reductions in lipoprotein(a) [Lp(a)] concentrations out to 1 year in adults with elevated Lp(a), extended data from the APOLLO phase 1 trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results